Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 512 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genotyping Clear all
Terminated Phase 2 Interventional Results available

Rucaparib in Nonmetastatic prOstAte With BRCAness

NCT03533946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Rucaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms
Interventions
tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensitive Periods in Early Flavor Learning

NCT00994747
View directory record Official record
Conditions
Healthy
Interventions
Nutramigen (Flavor and Type of Infant Formula), Enfamil, milk-based formula
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
2 Weeks to 4 Weeks
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 28, 2026, 12:49 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

NCT07232355
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Not listed
Lead sponsor
Atila Biosystems Inc.
Industry
Eligibility
30 Years to 64 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Not applicable Interventional

Healthy Eating Through Reduction Of Excess Sugar

NCT02948647
View directory record Official record
Conditions
NAFLD
Interventions
Standard of care plus sugar-reduction education
Other
Lead sponsor
University of Southern California
Other
Eligibility
12 Years to 18 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 28, 2026, 12:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

NCT05216042
View directory record Official record
Conditions
Cardiovascular Diseases, Natriuretic Peptides, Cardiometabolic Diseases, Energy Expenditure, Glucose Metabolism, Exercise, Obesity
Interventions
Study diet, Exercise capacity VO2 max determination, Exercise Challenge, Glucose Challenge
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

NCT00869661
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 28, 2026, 12:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genotype and Phenotype Registry: Enrollment of Normal Control Subjects for Current and Future Research

NCT00926042
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
4,511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

NCT01768286
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

NCT00968357
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

NCT02378935
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Green Tea and Reduction of Breast Cancer Risk

NCT00917735
View directory record Official record
Conditions
Breast Cancer
Interventions
Green tea extract supplement, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
1,075 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
5
States / cities
Edina, Minnesota • Maple Grove, Minnesota • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 28, 2026, 12:49 PM EDT
Terminated No phase listed Observational

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

NCT02315638
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
Tacere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

NCT01221298
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

NCT02114177
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

NCT00266318
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon Alfacon-1 and Ribavirin
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2008 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

NCT02304159
View directory record Official record
Conditions
Hepatitis C, Cirrhosis
Interventions
daclatasvir, Sofosbuvir, Sovaldi, Ribavirin
Drug
Lead sponsor
Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 28, 2026, 12:49 PM EDT
Not listed Phase 4 Interventional

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00005000
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 12:49 PM EDT
Recruiting Not applicable Interventional

PKU Protein Requirements

NCT07194993
View directory record Official record
Conditions
PKU
Interventions
Nonradioactive stable oral isotope, Test diet
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

NCT00863239
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
Drug
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Chula Vista, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 28, 2026, 12:49 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

NCT06972407
View directory record Official record
Conditions
Genetic Predisposition, Type2diabetes
Interventions
Exendin 9-39, Saline
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 28, 2026, 12:49 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 28, 2026, 12:49 PM EDT
Terminated Not applicable Interventional Results available

Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

NCT00578344
View directory record Official record
Conditions
Sickle Cell Disease, Hemoglobin SC
Interventions
Busulfan, Campath 1H, Cyclophosphamide and MESNA
Drug · Biological
Lead sponsor
Tami D. John
Other
Eligibility
Up to 40 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 28, 2026, 12:49 PM EDT